Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Giles, F J
Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. [electronic resource] - Cancer Jul 2001 - 406-13 p. digital
Publication Type: Journal Article
0008-543X
10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u doi
Adolescent
Adult
Aged
Aminoglycosides
Anti-Bacterial Agents--adverse effects
Antibodies, Monoclonal--adverse effects
Antineoplastic Agents--adverse effects
Cohort Studies
Female
Hematopoietic Stem Cell Transplantation
Hepatic Veno-Occlusive Disease--diagnosis
Humans
Incidence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Male
Middle Aged
Myelodysplastic Syndromes--drug therapy
Retrospective Studies
Risk Factors
Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. [electronic resource] - Cancer Jul 2001 - 406-13 p. digital
Publication Type: Journal Article
0008-543X
10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u doi
Adolescent
Adult
Aged
Aminoglycosides
Anti-Bacterial Agents--adverse effects
Antibodies, Monoclonal--adverse effects
Antineoplastic Agents--adverse effects
Cohort Studies
Female
Hematopoietic Stem Cell Transplantation
Hepatic Veno-Occlusive Disease--diagnosis
Humans
Incidence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Male
Middle Aged
Myelodysplastic Syndromes--drug therapy
Retrospective Studies
Risk Factors